JP2009518415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518415A5 JP2009518415A5 JP2008544453A JP2008544453A JP2009518415A5 JP 2009518415 A5 JP2009518415 A5 JP 2009518415A5 JP 2008544453 A JP2008544453 A JP 2008544453A JP 2008544453 A JP2008544453 A JP 2008544453A JP 2009518415 A5 JP2009518415 A5 JP 2009518415A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- solvate
- composition according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 24
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 229960003310 sildenafil Drugs 0.000 claims 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 3
- 230000008694 endothelial dysfunction Effects 0.000 claims 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 3
- 229960000835 tadalafil Drugs 0.000 claims 3
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 3
- 229960000438 udenafil Drugs 0.000 claims 3
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims 3
- 229960002381 vardenafil Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960004617 sapropterin Drugs 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Claims (15)
- ヒトにおける内皮機能不全を治療するための組成物であって、該内皮機能不全を治療するのに有効な量の（６Ｒ）−テトラヒドロビオプテリン（ＢＨ４）を含む組成物。
- 前記内皮機能不全が高血圧である、請求項１に記載の組成物。
- 前記ヒトが２型糖尿病に罹患している、請求項１または請求項２に記載の組成物。
- 前記組成物が経口で投与される、請求項１から３のいずれか一項に記載の組成物。
- 治療有効量が、１日当たり３ｍｇ／ｋｇ超〜約１５ｍｇ／ｋｇの範囲である、請求項１から４のいずれか一項に記載の組成物。
- 治療有効量が、１日当たり３ｍｇ／ｋｇ超〜約１０ｍｇ／ｋｇの範囲である、請求項１から４のいずれか一項に記載の組成物。
- 前記組成物中のＢＨ４が、１日当たり総用量約５ｍｇ／ｋｇで経口投与される、請求項１から３のいずれか一項に記載の組成物。
- 前記組成物中のＢＨ４が、１日当たり総用量約１０ｍｇ／ｋｇで経口投与される、請求項１から３のいずれか一項に記載の組成物。
- 前記組成物中のＢＨ４が、１日当たり総用量約４００ｍｇで経口投与される、請求項１から３のいずれか一項に記載の組成物。
- 前記組成物が１日２回投与される、請求項１から９のいずれか一項に記載の組成物。
- 前記組成物が、ＢＨ４以外の治療薬と組み合わせて投与される、請求項１から１０のいずれか一項に記載の組成物。
- 前記治療薬がＰＤＥ５阻害剤を含む、請求項１１に記載の組成物。
- 前記ＰＤＥ５阻害剤が、シルデナフィル、シルデナフィルの医薬として許容可能な塩、シルデナフィルの溶媒和物、タダラフィル、タダラフィルの医薬として許容可能な塩、タダラフィルの溶媒和物、バルデナフィル、バルデナフィルの医薬として許容可能な塩、バルデナフィルの溶媒和物、ウデナフィル、ウデナフィルの医薬として許容可能な塩、ウデナフィルの溶媒和物、およびそれらの混合物からなる群から選択される、請求項１２に記載の組成物。
- 前記ＰＤＥ５阻害剤が、シルデナフィルまたはその医薬として許容可能な塩もしくは溶媒和物を含む、請求項１２に記載の組成物。
- 鎌状赤血球症を治療するための組成物であって、該鎌状赤血球症を治療するのに有効な量の（６Ｒ）−テトラヒドロビオプテリン（ＢＨ４）を含む組成物。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74257805P | 2005-12-05 | 2005-12-05 | |
| US76497906P | 2006-02-03 | 2006-02-03 | |
| US81784706P | 2006-06-30 | 2006-06-30 | |
| PCT/US2006/046449 WO2007067570A1 (en) | 2005-12-05 | 2006-12-05 | Methods and compositions for the treatment of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518415A JP2009518415A (ja) | 2009-05-07 |
| JP2009518415A5 true JP2009518415A5 (ja) | 2011-01-27 |
Family
ID=37877059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544453A Withdrawn JP2009518415A (ja) | 2005-12-05 | 2006-12-05 | 疾患の処置のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090018136A1 (ja) |
| EP (1) | EP1965803A1 (ja) |
| JP (1) | JP2009518415A (ja) |
| AU (1) | AU2006321942A1 (ja) |
| CA (1) | CA2631740A1 (ja) |
| WO (1) | WO2007067570A1 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0517088A (pt) | 2004-11-17 | 2008-09-30 | Biomarin Pharm Inc | formulação de comprimido estável |
| KR101002490B1 (ko) * | 2007-06-09 | 2010-12-17 | 동아제약주식회사 | 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물 |
| AU2008347005B2 (en) | 2008-01-03 | 2013-10-03 | Biomarin Pharmaceutical Inc. | Pterin analog for treating BH4 responsive condition |
| AU2009248057B2 (en) * | 2008-05-13 | 2013-02-21 | Genmedica Therapeutics Sl | Salicylate conjugates useful for treating metabolic disorders |
| AU2010224866C1 (en) * | 2009-03-16 | 2015-01-15 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
| JP2011010865A (ja) | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
| WO2011019399A1 (en) * | 2009-08-13 | 2011-02-17 | Medstar Health Research Institute, Inc. | Preservation of blood vessels using phosphodiesterase inhibitors |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| AU2013292350B9 (en) * | 2012-07-19 | 2018-08-23 | Vifor Pharma Technology Ltd. | Compositions comprising crosslinked cation-binding polymers |
| US20150013695A1 (en) * | 2013-07-10 | 2015-01-15 | Ahkeo Ventures LLC | Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same |
| CN104530054B (zh) * | 2014-12-19 | 2018-01-19 | 扬子江药业集团有限公司 | 盐酸优克那非的多晶型物及其制备方法 |
| JP2020068734A (ja) * | 2018-11-01 | 2020-05-07 | 国立大学法人東京工業大学 | Ｓｐｒをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物 |
| WO2021009091A1 (en) * | 2019-07-15 | 2021-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating cardiac dysfunction |
| WO2022173818A1 (en) * | 2021-02-09 | 2022-08-18 | University Of Virginia Patent Foundation | Use of biliverdin reductase b inhibitors to allow malaria eradication in patients with g6pd deficiency |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2601215A (en) * | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
| US3505329A (en) * | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
| JPS5883691A (ja) * | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法 |
| JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| ZA836957B (en) * | 1982-09-20 | 1985-04-24 | Wellcome Found | Neurologically active chemical compounds |
| GB8318833D0 (en) * | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
| US5196533A (en) * | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
| US4587340A (en) * | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
| JPS60178887A (ja) * | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法 |
| JPS60199889A (ja) * | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法 |
| US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
| DE3437944A1 (de) * | 1984-10-17 | 1986-07-31 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt |
| US4713454A (en) * | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
| JPS61277618A (ja) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| EP0318926B1 (en) * | 1987-11-30 | 1995-05-03 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives |
| JP2534423B2 (ja) * | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
| US5198547A (en) * | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| DE4308739C1 (de) * | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
| US5945452A (en) * | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
| US5502050A (en) * | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| ES2177654T3 (es) * | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
| US20020076782A1 (en) * | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
| GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| US5922713A (en) * | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
| JP4306825B2 (ja) * | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
| US6200758B1 (en) * | 1999-02-19 | 2001-03-13 | New York State Office Of Mental Health | Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
| US6521212B1 (en) * | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| AU4013900A (en) * | 1999-03-19 | 2000-10-09 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
| GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| SE0000307D0 (sv) * | 2000-01-31 | 2000-01-31 | Univ Zuerich | Method and formulation för treatment of vasoconstriction |
| US6544994B2 (en) * | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
| US20050119270A1 (en) * | 2000-08-04 | 2005-06-02 | Mason R. P. | Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
| US20030007961A1 (en) * | 2001-06-22 | 2003-01-09 | Wilburn Michael D. | Orthomolecular vitamin E derivatives |
| US20030078231A1 (en) * | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
| US6685458B2 (en) * | 2001-10-11 | 2004-02-03 | Acushnet Company | Split metal die assembly with injection cycle monitor |
| WO2005018620A2 (en) * | 2003-08-26 | 2005-03-03 | Cell Center Cologne Gmbh | Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction |
| US7067659B2 (en) * | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
| JP2008523090A (ja) * | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| TW200719896A (en) * | 2005-04-18 | 2007-06-01 | Astrazeneca Ab | Combination product |
| CN101171005A (zh) * | 2005-05-11 | 2008-04-30 | 尼科梅德有限责任公司 | Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合 |
-
2006
- 2006-12-05 AU AU2006321942A patent/AU2006321942A1/en not_active Abandoned
- 2006-12-05 EP EP06839043A patent/EP1965803A1/en not_active Ceased
- 2006-12-05 JP JP2008544453A patent/JP2009518415A/ja not_active Withdrawn
- 2006-12-05 WO PCT/US2006/046449 patent/WO2007067570A1/en active Application Filing
- 2006-12-05 CA CA002631740A patent/CA2631740A1/en not_active Abandoned
-
2008
- 2008-06-05 US US12/134,023 patent/US20090018136A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518415A5 (ja) | ||
| US11065236B2 (en) | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | |
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2010536849A5 (ja) | ||
| JP2008533022A5 (ja) | ||
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| EP2283826A3 (en) | Galenic formulations of organic compounds | |
| JP2008515905A5 (ja) | ||
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2009517411A5 (ja) | ||
| JP2016539156A5 (ja) | ||
| JP2006508953A5 (ja) | ||
| HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
| WO2007054514A3 (en) | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure | |
| CA2668320A1 (en) | Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction | |
| JP2010518168A5 (ja) | ||
| JP2008513426A5 (ja) | ||
| WO2005082413A3 (en) | Ciclesonide and glycopyrronium combination | |
| JP2005517040A5 (ja) | ||
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| JP2006518731A5 (ja) | ||
| JP2008513427A5 (ja) | ||
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи |